Search

Author/Creator Middeke, Jan Moritz

1. Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor. Issue 14 (6th December 2021)

Authors:
Staber, Philipp Bernhard; Jurczak, Wojciech; Greil, Richard; Vucinic, Vladan; Middeke, Jan Moritz; Montillo, Marco; Munir, Talha; Neumeister, Peter; Schetelig, Johannes; Stilgenbauer, Stephan; Striebel, Frank; Dirnberger-Hertweck, Maren; Weirather, Johannes; Brugger, Wolfram; Kelemen, Peter; Wend...
Journal:
Leukemia & lymphoma
Issue:
Volume 62:Issue 14(2021)
Page Start:
3440
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Azacitidine and donor lymphocytes infusions in acute myeloid leukemia and myelodysplastic syndrome relapsed after allogeneic hematopoietic stem cell transplantation from alternative donors. (June 2022)

Authors:
Liberatore, Carmine; Stanghellini, Maria Teresa Lupo; Lorentino, Francesca; Vago, Luca; Carrabba, Matteo Giovanni; Greco, Raffaella; Marktel, Sarah; Assanelli, Andrea; Farina, Francesca; Corti, Consuelo; Bernardi, Massimo; Peccatori, Jacopo; Sockel, Katja; Middeke, Jan Moritz; Schetelig, Johannes...
Journal:
Therapeutic advances in hematology
Issue:
Volume 13(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Engrafting human regulatory T cells with a flexible modular chimeric antigen receptor technology. (June 2018)

Authors:
Koristka, Stefanie; Kegler, Alexandra; Bergmann, Ralf; Arndt, Claudia; Feldmann, Anja; Albert, Susann; Cartellieri, Marc; Ehninger, Armin; Ehninger, Gerhard; Middeke, Jan Moritz; Bornhäuser, Martin; Schmitz, Marc; Pietzsch, Jens; Akgün, Katja; Ziemssen, Tjalf; Steinbach, Jörg; Bachmann, Michael P.
Journal:
Journal of autoimmunity
Issue:
Volume 90(2018)
Page Start:
116
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. Issue 12 (December 2018)

Authors:
Platzbecker, Uwe; Middeke, Jan Moritz; Sockel, Katja; Herbst, Regina; Wolf, Dominik; Baldus, Claudia D; Oelschlägel, Uta; Mütherig, Anke; Fransecky, Lars; Noppeney, Richard; Bug, Gesine; Götze, Katharina S; Krämer, Alwin; Bochtler, Tilmann; Stelljes, Matthias; Groth, Christoph; Schubert, Antje; M...
Journal:
Lancet oncology
Issue:
Volume 19:Issue 12(2018)
Page Start:
1668
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Impact of pharmacokinetics on the toxicity and efficacy of clofarabine in patients with relapsed or refractory acute myeloid leukemia. Issue 12 (2nd December 2017)

Authors:
Büttner, Bozena; Knoth, Holger; Kramer, Michael; Oertel, Reinhard; Seeling, Andreas; Sockel, Katja; von Bonin, Malte; Stölzel, Friedrich; Alakel, Nael; Platzbecker, Uwe; Röllig, Christoph; Ehninger, Gerhard; Bornhäuser, Martin; Schetelig, Johannes; Middeke, Jan Moritz
Journal:
Leukemia & lymphoma
Issue:
Volume 58:Issue 12(2017)
Page Start:
2865
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Issue 9 (1st September 2016)

Authors:
Österborg, Anders; Udvardy, Miklós; Zaritskey, Andrey; Andersson, Per-Ola; Grosicki, Sebastian; Mazur, Grzegorz; Kaplan, Polina; Steurer, Michael; Schuh, Anna; Montillo, Marco; Kryachok, Iryna; Middeke, Jan Moritz; Kulyaba, Yaroslav; Rekhtman, Grygoriy; Gorczyca, Michele; Daly, Siobhan; Chang, Ch...
Journal:
Leukemia & lymphoma
Issue:
Volume 57:Issue 9(2016:Sep.)
Page Start:
2037
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗